MiRNA panels as biomarkers for bladder cancer

Biomarkers in Medicine

Volumn 8, Issue 5, 2014, Pages 733-746

  Tölle, Angelika ^a   Ratert, Nadine ^a,b   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

biomarker; bladder cancer; miRNAs; serum; tissue; urine

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 100; MICRORNA 10B; MICRORNA 125B; MICRORNA 126; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 15B; MICRORNA 182; MICRORNA 192; MICRORNA 200A; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 29B; TUMOR MARKER;

BLADDER CANCER; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE SEDIMENT; BLADDER TUMOR; GENETICS; METABOLISM; URINE;

HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84906259970     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.26     Document Type: Review

References (81)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urol. Esp. 36, 389-402 (2012).
3. van Rhijn BW, Burger M, Lotan Y et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 56, 430-442 (2009).
4. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classifcation of Malignant Tumours, 7th Edition. Wiley-Blackwell, NY, USA (2009).
5. Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fbroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol. Oncol. 31, 398-406 (2013).
6. Wu XR. Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev. 28, 281-290 (2009).
7. Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66, 35-63 (2005).
8. Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 99, 646-652 (2008).
9. Lotan Y, Shariat SF, Schmitz-Drager BJ et al. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 28, 441-448 (2010).
10. Soletormos G, Duffy MJ, Hayes DF et al. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin. Chem. 59, 52-59 (2013).
11. Kutter C, Svoboda P. miRNA, siRNA, piRNA: knowns of the unknown. RNA Biol. 5, 181-188 (2008).
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993).
13. Gregory RI, Yan KP, Amuthan G et al. The microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240 (2004).
14. Tetreault N, De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. Clin. Biochem. 46, 842-845 (2013).
15. Chelouf S, Dos Santos CO, Chong MM et al. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465, 584-589 (2010).
16. Schaefer A, Jung M, Kristiansen G et al. MicroRNAsand cancer: current state and future perspectives in urologic oncology. Urol. Oncol. 28(1), 4-13 (2010).
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004)
18. miRBase: the microRNA database. www.mirbase.org
19. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866 (2006).
20. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16, 415-421 (2004).
21. Heijnen HF, Schiel AE, Fijnheer R et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 94, 3791-3799 (1999).
22. Hunter MP, Ismail N, Zhang X et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3, e3694 (2008).
23. Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003-5008 (2011).
24. Turchinovich A, Weiz L, Langheinz A et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7223-7233 (2011).
25. Jung M, Schaefer A, Steiner I et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin. Chem. 56, 998-1006 (2010).
26. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
27. Liu CG, Calin GA, Meloon B et al. An oligonucleotide microchip for genome-wide microRNA profling in human and mouse tissues. Proc. Natl Acad. Sci. USA 101, 9740-9744 (2004).
28. Lu J, Getz G, Miska EA et al. MicroRNA expression profles classify human cancers. Nature 435, 834-838 (2005).
29. Schmittgen TD, Jiang J, Liu Q et al. A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res. 32, e43 (2004).
30. Chen C, Ridzon DA, Broomer AJ et al. Real-time quantifcation of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005).
31. Benes V, Castoldi M. Expression profling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50, 244-249 (2010).
32. van Rooij E. The art of microRNA research. Circ. Res. 108, 219-234 (2011).
33. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative realtime PCR experiments. Clin. Chem. 55, 611-622 (2009).
34. Ratert N, Meyer HA, Jung M et al. Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS ONE 7, e39309 (2012).
35. Baffa R, Fassan M, Volinia S et al. MicroRNA expression profling of human metastatic cancers identifes cancer gene targets. J. Pathol. 219, 214-221 (2009).
36. Cao Y, Yu SL, Wang Y et al. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumour Biol 32, 179-188 (2011).
37. Catto JW, Miah S, Owen HC et al. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res. 69, 8472-8481 (2009).
38. Dyrskjot L, Ostenfeld MS, Bramsen JB et al. Genomic profling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69, 4851-4860 (2009).
39. Friedman JM, Liang G, Liu CC et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69, 2623-2629 (2009).
40. Han Y, Chen J, Zhao X et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS ONE 6, e18286 (2011).
41. Hanke M, Hoefg K, Merz H et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28, 655-661 (2010).
42. Ichimi T, Enokida H, Okuno Y et al. Identifcation of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer 125, 345-352 (2009).
43. Lin T, Dong W, Huang J et al. MicroRNA-143 as a tumor suppressor for bladder cancer. J. Urol. 181, 1372-1380 (2009).
44. Lin Y, Wu J, Chen H et al. Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett. 586, 442-447 (2012).
45. Neely LA, Rieger-Christ KM, Neto BS et al. A microRNA expression ratio defning the invasive phenotype in bladder tumors. Urol. Oncol. 28, 39-48 (2010).
46. Ostenfeld MS, Bramsen JB, Lamy P et al. miR-145 induces caspase-dependent and-independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29, 1073-1084 (2010).
47. Song T, Xia W, Shao N et al. Differential miRNA expression profles in bladder urothelial carcinomas. Asian Pac. J. Cancer Prev. 11, 905-911 (2010).
48. Villadsen SB, Bramsen JB, Ostenfeld MS et al. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br. J. Cancer 106, 366-374 (2012).
49. Yamada Y, Enokida H, Kojima S et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 102, 522-529 (2011).
50. Hirata H, Hinoda Y, Ueno K et al. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33, 41-48 (2012).
51. Tatarano S, Chiyomaru T, Kawakami K et al. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int. J. Oncol. 39, 13-21 (2011).
52. Yoshino H, Chiyomaru T, Enokida H et al. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br. J. Cancer 104, 808-818 (2011).
53. Wang G, Zhang H, He H et al. Up-regulation of microRNA in bladder tumor tissue is not common. Int. Urol. Nephrol. 42, 95-102 (2010).
54. Sanders I, Holdenrieder S, Walgenbach-Brunagel G et al Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int. J. Urol. 19, 1017-1025 (2012).
55. Rosenberg E. Predicting progression of bladder urothelialcarcinoma using microRNA expression. BJU Int. 112(7), 1027-1034 (2013).
56. Gottardo F, Liu CG, Ferracin M et al. Micro-RNA profling in kidney and bladder cancers. Urol. Oncol. 25, 387-392 (2007).
57. Veerla S, Lindgren D, Kvist A et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer 124, 2236-2242 (2009).
58. Pignot G, Cizeron-Clairac G, Vacher S et al. MicroRNA expression profle in a large series of bladder tumors: Identifcation of a 3-mirna signature associated with aggressiveness of muscle-invasive bladder cancer. Int. J. Cancer 132(11), 2479-2491 (2012).
59. Ratert N, Meyer HA, Jung M et al. miRNA profling identifes candidate miRNAs for bladder cancer diagnosis and clinical outcome. J. Mol. Diagn. 15, 695-705 (2013).
60. Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M et al. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC. Med. Genomics 5, 40 (2012).
61. Wszolek MF, Rieger-Christ KM, Kenney PA et al. A microRNA expression profle defning the invasive bladder tumor phenotype. Urol. Oncol. 29(6), 794-801.e1 (2009).
62. Dip N, Reis ST, Timoszczuk LS et al. Stage, grade and behavior of bladder urothelial carcinoma defned by the microRNA expression profle. J. Urol. 188, 1951-1956 (2012).
63. Wiklund ED, Bramsen JB, Hulf T et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer 128, 1327-1334 (2011).
64. Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin. Cancer Res. 14, 5977-5983 (2008).
65. Snowdon J, Boag S, Feilotter H et al. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can. Urol. Assoc. J. 1-5 (2012).
66. Tolle A, Jung M, Rabenhorst S et al. Identifcation of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol. Rep. 30(4), 1949-1956 (2013).
67. Wang G, Chan ES, Kwan BC et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin. Genitourin. Cancer 10, 106-113 (2012).
68. Miah S, Dudziec E, Drayton RM et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br. J. Cancer 107, 123-128 (2012).
69. Mengual L, Lozano JJ, Ingelmo-Torres M et al. Using microRNA profling in urine samples to develop a noninvasive test for bladder cancer. Int. J. Cancer 133 (11), 2631-2641 (2013).
70. Yun SJ, Jeong P, Kim WT et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int. J. Oncol. 41, 1871-1878 (2012).
71. Simonato F, Ventura L, Sartori N et al. Detection of microRNAs in archival cytology urine smears. PLoS ONE 8, e57490 (2013).
72. Scheffer AR, Holdenrieder S, Kristiansen G et al. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J. Urol. 32(2), 353-358 (2012).
73. Adam L, Wszolek MF, Liu CG et al. Plasma microRNA profles for bladder cancer detection. Urol. Oncol. 31(8), 1701-1708 (2013).
74. Kenney PA, Wszolek MF, Rieger-Christ KM et al. Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 107, 656-663 (2011).
75. Keller A, Leidinger P, Bauer A et al. Toward the blood-borne miRNome of human diseases. Nat. Methods 8, 841-843 (2011).
76. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 36, e61-e67 (2012).
77. Mahn R, Heukamp LC, Rogenhofer S et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77, 1265-1216 (2011).
78. Zheng XH, Cui C, Zhou XX et al. Centrifugation: an important pre-analytic factor that infuences plasma microRNA quantifcation during blood processing. Chin J. Cancer 32(12), 667-672 (2013).
79. Brase JC, Johannes M, Schlomm T et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128, 608-616 (2011).
80. Gonzales JC, Fink LM, Goodman OB Jr et al. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specifc antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 9, 39-45 (2011).
81. Cheng H, Zhang L, Cogdell DE et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6, e17745 (2011).